HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 183 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,312,850 | -8.2% | 101,094 | -1.4% | 0.21% | +2.4% |
| Q2 2023 | $3,608,735 | -8.3% | 102,550 | -14.9% | 0.20% | -8.1% |
| Q1 2023 | $3,934,064 | -13.3% | 120,492 | +46.4% | 0.22% | -14.2% |
| Q4 2022 | $4,535,722 | -3.5% | 82,318 | -22.4% | 0.26% | -4.8% |
| Q3 2022 | $4,700,000 | -10.4% | 106,127 | -1.3% | 0.27% | +7.5% |
| Q2 2022 | $5,245,000 | -12.8% | 107,538 | -13.1% | 0.25% | +5.8% |
| Q1 2022 | $6,017,000 | +2.5% | 123,682 | -10.1% | 0.24% | +15.4% |
| Q4 2021 | $5,869,000 | +10.0% | 137,646 | -1.1% | 0.21% | +5.6% |
| Q3 2021 | $5,336,000 | +34.6% | 139,214 | -0.9% | 0.20% | +39.7% |
| Q2 2021 | $3,965,000 | -18.3% | 140,438 | -4.4% | 0.14% | -10.8% |
| Q1 2021 | $4,854,000 | +291.8% | 146,905 | +328.6% | 0.16% | +259.1% |
| Q4 2020 | $1,239,000 | – | 34,275 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $618,113,619 | 97.50% |
| venBio Partners LLC | 1,035,396 | $57,050,320 | 17.69% |
| Vivo Capital, LLC | 2,606,247 | $143,604 | 16.53% |
| Nan Fung Group Holdings Ltd | 368,665 | $20,313,442 | 14.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 264,500 | $14,560,725 | 4.50% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 685,340 | $37,762,234 | 3.51% |
| ASHFORD CAPITAL MANAGEMENT INC | 356,638 | $19,650,754 | 3.05% |
| TANG CAPITAL MANAGEMENT LLC | 281,200 | $15,494,120 | 2.25% |
| MPM BioImpact LLC | 139,377 | $7,679,673 | 1.99% |
| O'Neil Global Advisors, Inc. | 7,335 | $404 | 1.86% |